theophyllineWhat was measured
Measured, with no finding
243 endpoints
Show what was measuredHide what was measured
breathlessness
no effect
neither did Visual Analogue Score for breathlessness isn two small studies (WMD 3.6, 95%CI -4.6, 11.8)
PMID 12519617 · one of two readings recorded this
FEV1, pooled weighted mean difference, oral theophylline versus placebo in stable COPD (also FVC, VO2max, PaO2, PaCO2, walking distance, breathlessness VAS)
increases, WMD 100 ml; 95% CI 40, 160 ml
Not recorded as a finding: the supporting sentence never names the compound
FEV1 improved with treatment: Weighted Mean Difference (WMD) 100 ml; 95% Confidence Interval (95%CI) 40, 160 ml.
PMID 12519617 · one of two readings recorded this
FEV1, weighted mean difference versus placebo, oral theophylline in stable COPD
increases, WMD 100 ml (95% CI 40, 160 ml)
Not recorded as a finding: the supporting sentence never names the compound
FEV1 improved with treatment: Weighted Mean Difference (WMD) 100 ml; 95% Confidence Interval (95%CI) 40, 160 ml.
PMID 12519617 · one of two readings recorded this
FEV1
increases
FEV1 improved with treatment: Weighted Mean Difference (WMD) 100 ml; 95% Confidence Interval (95%CI) 40, 160 ml
PMID 12519617 · one of two readings recorded this
FVC
increases
Similarly for FVC: WMD 210 ml 95%CI 100, 320
PMID 12519617 · one of two readings recorded this
nausea
increases
The Relative Risk (RR) of nausea was greater with theophylline (RR 7.7; 95%CI 1.5, 39.9)
PMID 12519617 · one of two readings recorded this
PaCO2 at rest
decreases
At rest, PaO2 and PaCO2 both improved with treatment (WMD 3.2 mmHg; 95%CI = 1.2, 5., and WMD -2.4 mmHg; 95%CI = -3.5, -1.2, respectively)
PMID 12519617 · one of two readings recorded this
PaO2 at rest
increases
At rest, PaO2 and PaCO2 both improved with treatment (WMD 3.2 mmHg; 95%CI = 1.2, 5., and WMD -2.4 mmHg; 95%CI = -3.5, -1.2, respectively)
PMID 12519617 · one of two readings recorded this
patient preference
increases
However, patients' preference for theophylline was greater than that for placebo (RR 2.27; 95%CI = 1.26, 4.11)
PMID 12519617 · one of two readings recorded this
VO2max
increases
Two studies reported an improvement in VO2max; WMD 195 ml/min, 95%CI 113,27
PMID 12519617 · one of two readings recorded this
walking distance tests
no effect
Walking distance tests did not improve (4 studies, Standardised Mean Difference 0.30, 95%CI -0.01, 0.62)
PMID 12519617 · one of two readings recorded this
adverse events (any)
decreases
Participants taking salmeterol experienced fewer adverse events than those using theophylline (Parallel studies: Relative Risk 0.44; 95% CI 0.30 to 0.63, Risk Difference -0.11; 95% CI -0.16 to -0.07, Numbers Needed to Treat (NNT) 9; 95% CI 6 to 14)
PMID 17636663 · one of two readings recorded this
central nervous system adverse events
decreases
Significant reductions were reported for central nervous system adverse events (Relative Risk 0.50; 95% CI 0.29 to 0.86, Risk Difference -0.07; 95% CI -0.12 to -0.02, NNT 14; 95% CI 8 to 50)
PMID 17636663 · one of two readings recorded this
efficacy (bitolterol versus theophylline)
decreases
Bitolterol, used in only one study, was reported to be less effective than theophylline
PMID 17636663 · one of two readings recorded this
efficacy (formoterol versus theophylline)
no effect
Formoterol, used in two studies was reported to be as effective as theophylline
PMID 17636663 · one of two readings recorded this
evening PEF
increases
evening PEF (mean difference 15.58 L/min, 95% CI 8.33 to 22.83)
PMID 17636663 · one of two readings recorded this
FEV(1) predicted
no effect
There was no significant difference between salmeterol and theophylline in FEV(1) predicted (6.5%; 95% CI -0.84 to 13.83)
PMID 17636663 · one of two readings recorded this
FEV1 percent predicted, salmeterol versus oral sustained-release theophylline
no effect, 6.5% (95% CI -0.84 to 13.83)
Not recorded as a finding: the comparison was against another active treatment
There was no significant difference between salmeterol and theophylline in FEV(1) predicted (6.5%; 95% CI -0.84 to 13.83).
PMID 17636663 · one of two readings recorded this
FEV1 % predicted, pooled mean difference, salmeterol versus theophylline in asthma (also morning and evening PEF, rescue medication use, adverse events)
no effect, 6.5%; 95% CI -0.84 to 13.83 (salmeterol versus theophylline)
Not recorded as a finding: the comparison was against another active treatment
There was no significant difference between salmeterol and theophylline in FEV(1) predicted (6.5%; 95% CI -0.84 to 13.83).
PMID 17636663 · one of two readings recorded this
gastrointestinal adverse events
decreases
and gastrointestinal adverse events (Relative Risk 0.30; 95% CI 0.17 to 0.55, Risk Difference -0.11; 95% CI -0.16 to -0.06, NNT 9; 95% CI 6 to 16)
PMID 17636663 · one of two readings recorded this
morning PEF
increases
salmeterol treatment led to significantly better morning PEF (mean difference 16.71 L/min, 95% CI 8.91 to 24.51)
PMID 17636663 · one of two readings recorded this
short-acting beta-2 agonist requirement, daytime
decreases
There is evidence of decreased daytime and nighttime short-acting beta-2 agonist requirement with salmeterol
PMID 17636663 · one of two readings recorded this
short-acting beta-2 agonist requirement, nighttime
decreases
There is evidence of decreased daytime and nighttime short-acting beta-2 agonist requirement with salmeterol
PMID 17636663 · one of two readings recorded this
use of rescue medication
decreases
Salmeterol also reduced the use of rescue medication
PMID 17636663 · one of two readings recorded this
peak FEV1
increases, n = 800
Twelve studies with 800 patients combined contributed data for the analysis of peak FEV1, which showed a significant improvement of 96 mL over placebo (WMD 0.096 L; 95% CI=0.04–0.15)
PMID 18046863 · one of two readings recorded this
peak FEV1
increases, n = 400
For trough and peak FEV1, the largest contribution of data (400 patients) was derived from a single study that showed a significant improvement over placebo of 90 mL and 80 mL, respectively
PMID 18046863 · one of two readings recorded this
peak FVC
increases, n = 358
Ten studies with 358 patients combined contributed data for the analysis of peak FVC, which showed a significant improvement of 242 mL over placebo (WMD 0.242 L; 95% CI=0.11–0.37)
PMID 18046863 · one of two readings recorded this
peak (post-dose) FEV1, pooled weighted mean difference versus placebo
increases, WMD 0.096 L (95% CI 0.04-0.15), n = 800
Not recorded as a finding: The only sentence never names theophylline (it says 'over placebo' only), so it is not self-supporting on its own.
Twelve studies with 800 patients combined contributed data for the analysis of peak FEV1, which showed a significant improvement of 96 mL over placebo (WMD 0.096 L; 95% CI=0.04–0.15).
PMID 18046863 · one of two readings recorded this
peak (post-dose) FEV1, pooled WMD, oral theophylline versus placebo
increases, n = 800
Not recorded as a finding: the only sentence reporting it never names theophylline (it reads 'improvement of 96 mL over placebo'), so it is not self-supporting on its own
Twelve studies with 800 patients combined contributed data for the analysis of peak FEV1, which showed a significant improvement of 96 mL over placebo (WMD 0.096 L; 95% CI=0.04–0.15).
PMID 18046863 · one of two readings recorded this
peak (post-dose) forced vital capacity (FVC), pooled WMD, spirometry
increases, n = 358
Not recorded as a finding: no outcome node for forced vital capacity
Ten studies with 358 patients combined contributed data for the analysis of peak FVC, which showed a significant improvement of 242 mL over placebo (WMD 0.242 L; 95% CI=0.11–0.37).
PMID 18046863 · one of two readings recorded this
trough FEV1
increases, n = 704
Ten studies with 704 patients combined contributed data for the analysis of trough FEV1, which showed a significant improvement for theophylline of 108 mL over placebo (WMD 0.108 L; 95% CI=0.05–0.16)
PMID 18046863 · one of two readings recorded this
trough FEV1
increases, n = 400
For trough and peak FEV1, the largest contribution of data (400 patients) was derived from a single study that showed a significant improvement over placebo of 90 mL and 80 mL, respectively
PMID 18046863 · one of two readings recorded this
trough forced vital capacity (FVC), pooled WMD, spirometry
increases, n = 166
Not recorded as a finding: no outcome node for forced vital capacity
Six studies with 166 patients combined contributed data for the analysis of trough FVC, which showed a significant improvement of 186 mL over placebo (WMD 0.186 L; 95% CI=0.04–0.34).
PMID 18046863 · one of two readings recorded this
trough FVC
increases, n = 166
Six studies with 166 patients combined contributed data for the analysis of trough FVC, which showed a significant improvement of 186 mL over placebo (WMD 0.186 L; 95% CI=0.04–0.34)
PMID 18046863 · one of two readings recorded this
asthma exacerbation rate
unclear
eight patients (5.2%) with an increase in ICS dose and three patients (1.9%) with addition of theophylline reported exacerbations
PMID 21319345 · one of two readings recorded this
asthma exacerbation rate
no effect
Two trials examined exacerbation rates due to asthma, and their results showed there were no statistical differences in exacerbation rates between the groups
PMID 21319345 · one of two readings recorded this
evening peak expiratory flow (PEF)
no effect, p = 0.2
There was no difference between treatments in terms of morning (p = 0.77) or evening (p = 0.20) PEF
PMID 21319345 · one of two readings recorded this
evening peak expiratory flow (PEF)
increases
the increases in PEF with addition of theophylline were higher, by 11.20 liter/min (95% CI 9.14-13.25) in the morning and by 9.85 liter/min (95% CI 7.55-12.14) in the evening, than with increasing the dose of ICS for the strata of six-week duration
PMID 21319345 · one of two readings recorded this
evening peak expiratory flow (PEF)
no effect
For the strata of duration longer than six weeks, evening PEF showed no difference
PMID 21319345 · one of two readings recorded this
FEV1 as % predicted (FEV1pred)
increases, p = 0.00001
Addition of theophylline produced a significantly greater increase by 2.49% [weighted means difference (WMD) = 2.49; 95% CI 1.99-3.00; z = 9.70; p < 0.00001] than increasing the dose of ICS in FEV1pred
PMID 21319345 · one of two readings recorded this
FEV1 as % predicted (FEV1pred)
increases
The random effect duramodel of FEV1pred showed a pooled WMD of 2.51 (95% CI 1.82-3.20)
PMID 21319345 · one of two readings recorded this
FEV1 as % predicted (spirometry), pooled weighted mean difference, adding theophylline to inhaled corticosteroid versus increasing the inhaled corticosteroid dose in symptomatic asthma (also home PEF, rescue medication, exacerbations)
increases, WMD 2.49%; 95% CI 1.99-3.00
Not recorded as a finding: the comparison was against another active treatment
Addition of theophylline produced a significantly greater increase by 2.49% [weighted means difference (WMD) = 2.49; 95% CI 1.99-3.00; z = 9.70; p < 0.00001] than increasing the dose of ICS in FEV1pred.
PMID 21319345 · one of two readings recorded this
FEV1 percent predicted, adding theophylline to ICS versus increasing the ICS dose
increases, WMD 2.49% (95% CI 1.99-3.00)
Not recorded as a finding: the comparison was against another active treatment
Addition of theophylline produced a significantly greater increase by 2.49% [weighted means difference (WMD) = 2.49; 95% CI 1.99-3.00; z = 9.70; p < 0.00001] than increasing the dose of ICS in FEV1pred.
PMID 21319345 · one of two readings recorded this
morning peak expiratory flow (PEF)
no effect, p = 0.77
There was no difference between treatments in terms of morning (p = 0.77) or evening (p = 0.20) PEF
PMID 21319345 · one of two readings recorded this
morning peak expiratory flow (PEF)
increases
the increase in morning PEF was in favor of increasing the dose of ICS by 7.61 liter/min (95% CI 3.72-11.50)
PMID 21319345 · one of two readings recorded this
morning peak expiratory flow (PEF)
increases
the increases in PEF with addition of theophylline were higher, by 11.20 liter/min (95% CI 9.14-13.25) in the morning and by 9.85 liter/min (95% CI 7.55-12.14) in the evening, than with increasing the dose of ICS for the strata of six-week duration
PMID 21319345 · one of two readings recorded this
need for rescue medication
no effect
All four trials revealed improvement of symptom scores and need for rescue medication in both groups, and there was no significant difference between the two treatments
PMID 21319345 · one of two readings recorded this
plasma cortisol level
decreases
Evans, et al. reported that the reduction of plasma cortisol level was observed only in the group given an increased dose of ICS after 12-week treatment
PMID 21319345 · one of two readings recorded this
plasma cortisol level
no effect
Wang, et al. found there was no significant reduction in plasma cortisol in both treatments
PMID 21319345 · one of two readings recorded this
symptom scores
no effect
All four trials revealed improvement of symptom scores and need for rescue medication in both groups, and there was no significant difference between the two treatments
PMID 21319345 · one of two readings recorded this
abdominal pain
no effect
There were no differences in abdominal pain, psychological side effects, headaches, seizures, or tremor
PMID 29391776 · one of two readings recorded this
admission rate
no effect
In almost every case, there were no significant differences between theophylline and control
PMID 29391776 · one of two readings recorded this
cardiovascular adverse events
increases
Compared with placebo, IV theophylline caused more nausea, vomiting, and cardiovascular adverse events (such as palpitations and arrhythmias)
PMID 29391776 · one of two readings recorded this
cardiovascular adverse events
no effect
was not different from the active controls in terms of the frequency of psychological side effects, headaches, cardiovascular adverse events, tremor, CPK/CK elevation, or glucosuria/hyperglycemia
PMID 29391776 · one of two readings recorded this
CPK/CK elevation
no effect
was not different from the active controls in terms of the frequency of psychological side effects, headaches, cardiovascular adverse events, tremor, CPK/CK elevation, or glucosuria/hyperglycemia
PMID 29391776 · one of two readings recorded this
duration of hospital stay, intravenous theophylline versus pooled control (active comparators and placebo or no drug)
decreases, 0.23 hours shorter (95% CI -0.37 to -0.08 hours), p = 0.002
Not recorded as a finding: the comparison was against another active treatment
The exception was the duration of hospital stay, with theophylline reducing the duration of stay by 0.23 hours (14 minutes) (95% CI: −0.37, −0.08 hours, p=0.002).
PMID 29391776 · one of two readings recorded this
duration of hospital stay, pooled mean difference in hours, theophylline versus control
decreases, -0.23 hours (95% CI -0.37, -0.08), p=0.002, p = 0.002
Not recorded as a finding: the pooled control is a mixture of active comparators, placebo and no drug, so the contrast is not theophylline against its absence; no placebo-only estimate is stated
The exception was the duration of hospital stay, with theophylline reducing the duration of stay by 0.23 hours (14 minutes) (95% CI: −0.37, −0.08 hours, p=0.002).
PMID 29391776 · one of two readings recorded this
duration of hospital stay
decreases, p = 0.002
The exception was the duration of hospital stay, with theophylline reducing the duration of stay by 0.23 hours (14 minutes) (95% CI: −0.37, −0.08 hours, p=0.002)
PMID 29391776 · one of two readings recorded this
FEV1 as percent of predicted
no effect, p = 0.13
Pooling of the six studies measuring FEV1 as a percent of predicted showed no difference between theophylline and control (MD =3.78 [95% CI: −1.08, 8.63], p=0.13, data not shown)
PMID 29391776 · one of two readings recorded this
FEV1
no effect, p = 0.07
Intravenous (IV) theophylline was not significantly different from adrenaline (p=0.12), a leukotriene receptor antagonist (p=0.81), or placebo (p=0.07) in increasing FEV1
PMID 29391776 · one of two readings recorded this
FEV1
no effect, p = 0.12
Intravenous (IV) theophylline was not significantly different from adrenaline (p=0.12), a leukotriene receptor antagonist (p=0.81), or placebo (p=0.07) in increasing FEV1
PMID 29391776 · one of two readings recorded this
FEV1
decreases, p = 0.001
A pooled analysis of all active controls, however, also showed a small but significantly improved FEV1 in the control compared with theophylline (MD =−0.14L [95% CI: −0.25, −0.02], p=0.001; Figure 3B)
PMID 29391776 · one of two readings recorded this
FEV1
decreases, p = 0.002
was significantly worse than beta-2 agonists (mean difference [MD] =−0.20 L [95% CI: −0.34, −0.07], p=0.002)
PMID 29391776 · one of two readings recorded this
FEV1
no effect, p = 0.81
Intravenous (IV) theophylline was not significantly different from adrenaline (p=0.12), a leukotriene receptor antagonist (p=0.81), or placebo (p=0.07) in increasing FEV1
PMID 29391776 · one of two readings recorded this
FEV1
no effect
where patients were given bronchodilators with or without steroids, there was no significant differences between theophylline and control
PMID 29391776 · one of two readings recorded this
FEV1
decreases, p = 0.00001
In studies where the background medication was oxygen only or no additional medication other than the study drug, the control drugs performed better than theophylline (p<0.00001)
PMID 29391776 · one of two readings recorded this
FEV1
no effect, p = 0.18
although the difference between blinded and unblinded studies was not significant (p=0.18)
PMID 29391776 · one of two readings recorded this
FVC
no effect, p = 0.73
There was no difference in FVC between theophylline and control groups (p=0.73)
PMID 29391776 · one of two readings recorded this
glucosuria/hyperglycemia
no effect
was not different from the active controls in terms of the frequency of psychological side effects, headaches, cardiovascular adverse events, tremor, CPK/CK elevation, or glucosuria/hyperglycemia
PMID 29391776 · one of two readings recorded this
headaches
no effect
There were no differences in abdominal pain, psychological side effects, headaches, seizures, or tremor
PMID 29391776 · one of two readings recorded this
headaches
no effect
was not different from the active controls in terms of the frequency of psychological side effects, headaches, cardiovascular adverse events, tremor, CPK/CK elevation, or glucosuria/hyperglycemia
PMID 29391776 · one of two readings recorded this
heart rate change after intravenous theophylline, beats per minute, in the placebo-controlled trials
no effect, no significant difference, p=0.79, p = 0.79
Not recorded as a finding: the placebo-subgroup sentence is agentless and never names theophylline; the resting-heart-rate node also requires a stated rest position and period, which acute-asthma patients do not have
In the placebo-controlled trials, no significant difference was noted (p=0.79).
PMID 29391776 · one of two readings recorded this
heart rate
no effect, p = 0.79
In the placebo-controlled trials, no significant difference was noted (p=0.79)
PMID 29391776 · one of two readings recorded this
heart rate
decreases, p = 0.01
In the active control studies, theophylline lowered the heart rate by 5.17 bpm more than active controls, and this difference was significant (p=0.01)
PMID 29391776 · one of two readings recorded this
heart rate
no effect, p = 0.32
At longer-term time points (24–36 hours post-infusion), the difference in heart rate between IV theophylline and control treatments was similar (−3.59 bpm), but failed to reach statistical significance (p=0.32)
PMID 29391776 · one of two readings recorded this
heart rate
decreases, p = 0.02
In the short-term (30 minutes–3 hours post-infusion), theophylline lowered the heart rate by 4.17 beats per minute (bpm) compared with control therapy, which was significant (p=0.02)
PMID 29391776 · one of two readings recorded this
nausea
increases
Compared with placebo, IV theophylline caused more nausea, vomiting, and cardiovascular adverse events (such as palpitations and arrhythmias)
PMID 29391776 · one of two readings recorded this
nausea
increases
Compared with active comparators, theophylline again caused more nausea and vomiting
PMID 29391776 · one of two readings recorded this
oxygen saturation
no effect
In almost every case, there were no significant differences between theophylline and control
PMID 29391776 · one of two readings recorded this
PEFR as percent of predicted
no effect, p = 0.44
neither the short-term studies (30 minutes–2 hours; p=0.56) nor the longer-term studies (5 hours–48 hours; p=0.44) showed any significant differences between theophylline and control groups
PMID 29391776 · one of two readings recorded this
PEFR as percent of predicted
no effect, p = 0.56
neither the short-term studies (30 minutes–2 hours; p=0.56) nor the longer-term studies (5 hours–48 hours; p=0.44) showed any significant differences between theophylline and control groups
PMID 29391776 · one of two readings recorded this
PEFR (L)
no effect
There were no significant differences between theophylline and control at either time point
PMID 29391776 · one of two readings recorded this
PEFR (L)
no effect
There were no significant differences between theophylline and control at either time point
PMID 29391776 · one of two readings recorded this
psychological side effects
no effect
There were no differences in abdominal pain, psychological side effects, headaches, seizures, or tremor
PMID 29391776 · one of two readings recorded this
psychological side effects
no effect
was not different from the active controls in terms of the frequency of psychological side effects, headaches, cardiovascular adverse events, tremor, CPK/CK elevation, or glucosuria/hyperglycemia
PMID 29391776 · one of two readings recorded this
respiratory rate
no effect, p = 0.08
Theophylline was slightly less effective at lower respiratory rate, although this was not significant (p=0.08)
PMID 29391776 · one of two readings recorded this
seizures
no effect
There were no differences in abdominal pain, psychological side effects, headaches, seizures, or tremor
PMID 29391776 · one of two readings recorded this
symptom scores
no effect
In almost every case, there were no significant differences between theophylline and control
PMID 29391776 · one of two readings recorded this
symptom scores
no effect, p = 0.38
We found that there was no significant difference between adults and children in terms of symptoms (p=0.38)
PMID 29391776 · one of two readings recorded this
tremor
no effect
There were no differences in abdominal pain, psychological side effects, headaches, seizures, or tremor
PMID 29391776 · one of two readings recorded this
tremor
no effect
was not different from the active controls in terms of the frequency of psychological side effects, headaches, cardiovascular adverse events, tremor, CPK/CK elevation, or glucosuria/hyperglycemia
PMID 29391776 · one of two readings recorded this
use of rescue medication
no effect
In almost every case, there were no significant differences between theophylline and control
PMID 29391776 · one of two readings recorded this
vomiting
increases
Compared with placebo, IV theophylline caused more nausea, vomiting, and cardiovascular adverse events (such as palpitations and arrhythmias)
PMID 29391776 · one of two readings recorded this
vomiting
increases
Compared with active comparators, theophylline again caused more nausea and vomiting
PMID 29391776 · one of two readings recorded this
BSCC breathing component score
decreases, p = 0.0001
Breathing | 1.93 (0.83) | 1.41 (0.77) | 1.93 (0.77) | 1.67 (0.78) | −0.279 (–0.381, –0.177) | <0.0001
PMID 31240995 · one of two readings recorded this
BSCC cough component score
decreases, p = 0.0002
Cough | 1.71 (0.84) | 1.25 (0.71) | 1.65 (0.86) | 1.41 (0.75) | −0.193 (–0.294, –0.092) | 0.0002
PMID 31240995 · one of two readings recorded this
BSCC sputum component score
decreases, p = 0.0001
Sputum | 1.51 (0.84) | 1.14 (0.72) | 1.38 (0.83) | 1.27 (0.75) | −0.208 (–0.308, –0.108) | 0.0001
PMID 31240995 · one of two readings recorded this
COPD exacerbation rate per patient
decreases
Exacerbation rates were 43.5% lower in the BUD/FORM plus I + T group (rate 0.069 per patient per 12 weeks; 95% CI: 0.044, 0.106) than the I + T group (rate 0.121
PMID 31240995 · one of two readings recorded this
COPD exacerbation rate ratio
decreases, p = 0.0425
of 0.565 (95% CI: 0.325, 0.981; p = 0.0425)
PMID 31240995 · one of two readings recorded this
daytime reliever medication use, last week on treatment
decreases, p = 0.0102
mean of last week on treatment 0.97 vs 1.21, respectively; between-treatment difference −0.297 (95% CI: −0.522, −0.071); p = 0.0102
PMID 31240995 · one of two readings recorded this
discontinuation rate
decreases
(10.6% versus 5.5%)
PMID 31240995 · one of two readings recorded this
night-time reliever medication use, between-group difference
no effect, p = 0.2281
However, the between group difference was not statistically significant [–0.055 (95% CI −0.144, 0.035); p = 0.2281]
PMID 31240995 · one of two readings recorded this
night-time reliever medication use
decreases
from a mean of 0.34 doses per night at baseline to 0.26 doses per night during the last week of treatment in the BUD/FORM plus I + T group
PMID 31240995 · one of two readings recorded this
night-time reliever medication use
decreases
from 0.31 doses per night to 0.30 doses per night in the I + T group
PMID 31240995 · one of two readings recorded this
postdose FEV1 (5 min), change from baseline to treatment period
increases, p = 0.0001
Postdose FEV1 (5 min) (l) a, d | 0.90 | 0.89 | 1.06 | 0.98 | 6.7% | 1.067 | 1.044, 1.090 | <0.0001
PMID 31240995 · one of two readings recorded this
postdose FEV1 (60 min), change from baseline to treatment period
increases, p = 0.0001
Postdose FEV1 (60 min) (l) a, d | 0.90 | 0.89 | 1.09 | 1.01 | 6.8% | 1.068 | 1.043, 1.092 | <0.0001
PMID 31240995 · one of two readings recorded this
postdose FVC (5 min), change from baseline to treatment period
increases, p = 0.0001
Postdose FVC (5 min) (l) a, d | 2.06 | 2.04 | 2.38 | 2.26 | 4.5% | 1.045 | 1.024, 1.065 | <0.0001
PMID 31240995 · one of two readings recorded this
postdose FVC (60 min), change from baseline to treatment period
increases, p = 0.0003
Postdose FVC (60 min) (l) a, d | 2.06 | 2.04 | 2.42 | 2.32 | 3.8% | 1.038 | 1.017, 1.060 | 0.0003
PMID 31240995 · one of two readings recorded this
postdose IC (60 min), change from baseline to treatment period
increases, p = 0.0074
Postdose IC (60 min) (l) a, d | 1.70 | 1.70 | 1.97 | 1.89 | 3.8% | 1.038 | 1.010, 1.067 | 0.0074
PMID 31240995 · one of two readings recorded this
postdose morning PEF (5 min), change from baseline to treatment period
increases, p = 0.0001
Postdose morning PEF (5 min) (l/min) b | 159 | 160 | 190 | 164 | 27 | NR | 18.906, 35.431 | <0.0001
PMID 31240995 · one of two readings recorded this
predose FEV1, change from baseline to treatment period
increases, p = 0.0001
Predose FEV1 (l) a, c | 0.90 | 0.89 | 0.97 | 0.91 | 6.9% | 1.069 | 1.043, 1.096 | <0.0001
PMID 31240995 · one of two readings recorded this
predose FEV1, percent increase from baseline at end of study
increases
increased from baseline by 7.9% in the BUD/FORM plus I + T group compared with 0.9% in the I + T group
PMID 31240995 · one of two readings recorded this
predose FVC, change from baseline to treatment period
increases, p = 0.0007
Predose FVC (l) a, c | 2.06 | 2.04 | 2.19 | 2.10 | 4.0% | 1.040 | 1.017, 1.064 | <0.0007
PMID 31240995 · one of two readings recorded this
predose IC, change from baseline to treatment period
increases, p = 0.0248
Predose IC (l) a, c | 1.70 | 1.70 | 1.82 | 1.75 | 3.5% | 1.035 | 1.004, 1.066 | 0.0248
PMID 31240995 · one of two readings recorded this
predose morning PEF, change from baseline to treatment period
increases, p = 0.0001
Predose morning PEF (l/min) b, e | 159 | 160 | 185 | 162 | 23 | NR | 14.927, 31.161 | <0.0001
PMID 31240995 · one of two readings recorded this
SGRQ-C clinically significant improvement (reduction of 4 units or more)
increases, p = 0.002
In the BUD/FORM plus I + T group, 62.5% of patients experienced a clinically significant improvement in SGRQ-C score (reduction of ⩾4 units) compared with 49.7% of the I + T group (p = 0.002)
PMID 31240995 · one of two readings recorded this
SGRQ-C total score at baseline
The mean (SD) SGRQ-C total score at baseline was 67.12 (17.22) in the BUD/FORM
PMID 31240995 · one of two readings recorded this
SGRQ-C total score at baseline
plus I + T group and 65.18 (16.89) in the I + T group
PMID 31240995 · one of two readings recorded this
SGRQ-C total score improvement from baseline to study end
decreases, p = 0.0001
group compared with I + T alone (p < 0.0001)
PMID 31240995 · one of two readings recorded this
time to discontinuation
increases, p = 0.015
shorter time to discontinuation (p = 0.015)
PMID 31240995 · one of two readings recorded this
time to first COPD exacerbation
unclear
events) for BUD/FORM plus I + T versus I + T was 0.604 (95% CI: 0.339, 1.078;
PMID 31240995 · one of two readings recorded this
breathlessness
no effect
Low-dose theophylline had no significant effects on lung function (i.e. FEV1), incidence of pneumonia, mortality, breathlessness or measures of quality of life or disease impact
PMID 31343402 · one of two readings recorded this
hospital admissions due to COPD exacerbation
decreases, adjusted IRR 0.72, 95% CI 0.55 to 0.94
Not recorded as a finding: no outcome node for COPD exacerbation hospital admission
Hospital admissions due to COPD exacerbation were less frequent with low-dose theophylline (adjusted IRR 0.72, 95% CI 0.55 to 0.94).
PMID 31343402 · both readings recorded this
hospital admissions due to COPD exacerbation
decreases
Hospital admissions due to COPD exacerbation were less frequent with low-dose theophylline (adjusted IRR 0.72, 95% CI 0.55 to 0.94)
PMID 31343402 · one of two readings recorded this
incidence of pneumonia
no effect
Low-dose theophylline had no significant effects on lung function (i.e. FEV1), incidence of pneumonia, mortality, breathlessness or measures of quality of life or disease impact
PMID 31343402 · one of two readings recorded this
lung function (FEV1)
no effect
Low-dose theophylline had no significant effects on lung function (i.e. FEV1), incidence of pneumonia, mortality, breathlessness or measures of quality of life or disease impact
PMID 31343402 · one of two readings recorded this
measures of quality of life or disease impact
no effect
Low-dose theophylline had no significant effects on lung function (i.e. FEV1), incidence of pneumonia, mortality, breathlessness or measures of quality of life or disease impact
PMID 31343402 · one of two readings recorded this
mortality, 1-year follow-up, cause not stated
no effect
Not recorded as a finding: The all-cause-mortality node needs the horizon and a death-from-any-cause definition; the abstract states neither and the null sits inside a multi-endpoint sentence.
Low-dose theophylline had no significant effects on lung function (i.e. FEV1), incidence of pneumonia, mortality, breathlessness or measures of quality of life or disease impact.
PMID 31343402 · one of two readings recorded this
mortality, horizon not stated in the abstract (lumped into one sentence with lung function, pneumonia, breathlessness and quality of life)
no effect
Not recorded as a finding: all-cause-mortality node requires the follow-up horizon and the abstract does not say the deaths are all-cause; abstract-only paper, extracted conservatively
Low-dose theophylline had no significant effects on lung function (i.e. FEV1), incidence of pneumonia, mortality, breathlessness or measures of quality of life or disease impact.
PMID 31343402 · one of two readings recorded this
mortality
no effect
Low-dose theophylline had no significant effects on lung function (i.e. FEV1), incidence of pneumonia, mortality, breathlessness or measures of quality of life or disease impact
PMID 31343402 · one of two readings recorded this
number of participant-reported exacerbations treated with antibiotics and/or oral corticosteroids
no effect
The mean number of exacerbations was 2.24 (SD 1.99) for participants allocated to theophylline and 2.23 (SD 1.97) for participants allocated to placebo [adjusted incidence rate ratio (IRR) 0.99, 95% confidence interval (CI) 0.91 to 1.08]
PMID 31343402 · one of two readings recorded this
participant-reported COPD exacerbations treated with antibiotics and/or oral corticosteroids, per person-year
no effect, adjusted IRR 0.99, 95% CI 0.91 to 1.08
Not recorded as a finding: no outcome node for COPD exacerbation rate (primary outcome); the abstract sentence naming theophylline is not a single-sentence whole-study quote
The mean number of exacerbations was 2.24 (SD 1.99) for participants allocated to theophylline and 2.23 (SD 1.97) for participants allocated to placebo [adjusted incidence rate ratio (IRR) 0.99, 95% confidence interval (CI) 0.91 to 1.08].
PMID 31343402 · one of two readings recorded this
participants who ceased trial medication
no effect
A higher than expected percentage of participants (26%) ceased trial medication
PMID 31343402 · one of two readings recorded this
reporting of theophylline side effects
no effect
There were no differences in the reporting of theophylline side effects between the theophylline and placebo arms
PMID 31343402 · one of two readings recorded this
COPD exacerbation frequency, pooled hazard ratio
no effect, HR 1.08, 95% CI 0.97 to 1.19, I2 = 95.2%
Not recorded as a finding: no outcome node for COPD exacerbation rate
The meta-analysis result demonstrated that theophylline as an add-on therapy to ICS was not associated with the reduction of COPD exacerbation (HR: 1.08, 95%CI: 0.97 to 1.19, I 2 = 95.2%, Fig 2).
PMID 34029327 · one of two readings recorded this
COPD exacerbation (HR)
no effect
The meta-analysis result demonstrated that theophylline as an add-on therapy to ICS was not associated with the reduction of COPD exacerbation (HR: 1.08, 95%CI: 0.97 to 1.19, I 2 = 95.2%, Fig 2)
PMID 34029327 · one of two readings recorded this
COPD exacerbation (HR)
increases
the result demonstrated that high-dose theophylline led to a significant increase in COPD exacerbation
PMID 34029327 · one of two readings recorded this
COPD exacerbation (HR)
no effect
RCTs and cohort studies both indicated that adding theophylline to ICS did not reduce COPD exacerbation
PMID 34029327 · one of two readings recorded this
COPD exacerbation (HR)
no effect
RCTs and cohort studies both indicated that adding theophylline to ICS did not reduce COPD exacerbation
PMID 34029327 · one of two readings recorded this
COPD hospitalisation rate, pooled hazard ratio
increases, HR 1.12, 95% CI 1.10 to 1.15, I2 = 20.4%
Not recorded as a finding: no outcome node for COPD hospitalisation rate
In this meta-analysis, the theophylline group demonstrated a higher hospitalization rate compared with the non-theophylline group (HR: 1.12, 95%CI: 1.10 to 1.15, I 2 = 20.4%, Fig 4).
PMID 34029327 · one of two readings recorded this
FEV1
increases
This study demonstrated that the theophylline group showed significant improvement in FEV1
PMID 34029327 · one of two readings recorded this
HDAC activity
no effect
a double-blind RCT by Cosio et al. reported that the HDAC activity and inflammatory biomarkers were not different in both groups either at baseline or at the end of the study
PMID 34029327 · one of two readings recorded this
HDAC activity
increases
The results described that the theophylline arm was associated with a statistically significant increase in HDAC activity and a further reduction in TNF-⍺ and IL-8 concentrations in the sputum compared with the non-theophylline arm
PMID 34029327 · one of two readings recorded this
hospitalization rate (HR)
increases
the theophylline group demonstrated a higher hospitalization rate compared with the non-theophylline group (HR: 1.12, 95%CI: 1.10 to 1.15, I 2 = 20.4%, Fig 4)
PMID 34029327 · one of two readings recorded this
IL-8 concentration
decreases
The results described that the theophylline arm was associated with a statistically significant increase in HDAC activity and a further reduction in TNF-⍺ and IL-8 concentrations in the sputum compared with the non-theophylline arm
PMID 34029327 · one of two readings recorded this
inflammatory biomarkers
no effect
a double-blind RCT by Cosio et al. reported that the HDAC activity and inflammatory biomarkers were not different in both groups either at baseline or at the end of the study
PMID 34029327 · one of two readings recorded this
mortality (HR)
increases
the theophylline group was associated with an increased mortality of COPD patients compared with the non-theophylline group (HR: 1.19, 95%CI: 1.14 to 1.25, I 2 = 0%, Fig 5)
PMID 34029327 · one of two readings recorded this
mortality of COPD patients, pooled hazard ratio, theophylline plus ICS versus ICS without theophylline
increases, HR 1.19 (95%CI 1.14 to 1.25)
Not recorded as a finding: the paper never states the instrument the node requires
Similarly, the theophylline group was associated with an increased mortality of COPD patients compared with the non-theophylline group (HR: 1.19, 95%CI: 1.14 to 1.25, I 2 = 0%, Fig 5).
PMID 34029327 · one of two readings recorded this
publication bias (Egger's test)
no effect, p = 0.419
these results did not show any evidence of obvious bias (Egger’s test, P = 0.419, S4 Fig)
PMID 34029327 · one of two readings recorded this
TNF-⍺ concentration
decreases
The results described that the theophylline arm was associated with a statistically significant increase in HDAC activity and a further reduction in TNF-⍺ and IL-8 concentrations in the sputum compared with the non-theophylline arm
PMID 34029327 · one of two readings recorded this
ADC at 3 h follow-up
no effect, p = 0.34
ADC—(SD), mm2/s | 650 (109) | 610 (115) | 0.34a | 770 (72) | 740 (75) | 0.31a | 798 (29) | 803 (34) | 0.88a
PMID 34259904 · one of two readings recorded this
ADC at 3 h follow-up
no effect, p = 0.31
ADC—(SD), mm2/s | 650 (109) | 610 (115) | 0.34a | 770 (72) | 740 (75) | 0.31a | 798 (29) | 803 (34) | 0.88a
PMID 34259904 · one of two readings recorded this
ADC at 3 h follow-up
no effect, p = 0.88
ADC—(SD), mm2/s | 650 (109) | 610 (115) | 0.34a | 770 (72) | 740 (75) | 0.31a | 798 (29) | 803 (34) | 0.88a
PMID 34259904 · one of two readings recorded this
ADC at baseline
no effect, p = 0.66
ADC—(SD), mm2/s | 449 (24) | 450 (27) | 0.66a | 823 (179) | 762 (62) | 0.66a | 826 (46) | 843 (84) | 0.71a
PMID 34259904 · one of two readings recorded this
ADC at baseline
no effect, p = 0.66
ADC—(SD), mm2/s | 449 (24) | 450 (27) | 0.66a | 823 (179) | 762 (62) | 0.66a | 826 (46) | 843 (84) | 0.71a
PMID 34259904 · one of two readings recorded this
ADC at baseline
no effect, p = 0.71
ADC—(SD), mm2/s | 449 (24) | 450 (27) | 0.66a | 823 (179) | 762 (62) | 0.66a | 826 (46) | 843 (84) | 0.71a
PMID 34259904 · one of two readings recorded this
ADC change from baseline to 3 h
no effect, p = 0.35
ADC—(SD), mm2/s | 201 (101) | 159 (110) | 0.35a | −53 (195) | −22 (29) | 0.61a | −29 (54) | −40 (78) | 0.67a
PMID 34259904 · one of two readings recorded this
ADC change from baseline to 3 h
no effect, p = 0.61
ADC—(SD), mm2/s | 201 (101) | 159 (110) | 0.35a | −53 (195) | −22 (29) | 0.61a | −29 (54) | −40 (78) | 0.67a
PMID 34259904 · one of two readings recorded this
ADC change from baseline to 3 h
no effect, p = 0.67
ADC—(SD), mm2/s | 201 (101) | 159 (110) | 0.35a | −53 (195) | −22 (29) | 0.61a | −29 (54) | −40 (78) | 0.67a
PMID 34259904 · one of two readings recorded this
change in heart rate from baseline to 3-h follow-up, beats per minute
increases, mean increase 11 bpm (SD 26) versus mean decrease 9 bpm (SD 14), p < 0.05, n = 24
Not recorded as a finding: resting-heart-rate node requires seated or supine measurement after a stated rest period; the paper states neither position nor rest period for this acute-stroke measurement
The change in heart rate from baseline to 3‑h follow-up was significantly different (p < 0.05) in the theophylline group (mean increase by 11 beats per minute, SD 26) compared to the control group (mean decrease by 9 beats per minute, SD 14).
PMID 34259904 · one of two readings recorded this
clinical improvement at 3 h follow-up (NIHSS improvement of 4 points or more)
no effect, p = 1
Clinical improvement at 3‑h follow-up was present in 1 (8%) patient in the theophylline group and 2 patients (18%) in the control group (p = 1.0)
PMID 34259904 · one of two readings recorded this
diastolic blood pressure change from baseline to 3 h follow-up
no effect, p = 0.51
The change in systolic blood pressure (−12 mm Hg, SD 14 versus −8 mm Hg, SD 25; p = 0.62) and the diastolic blood pressure (−9 mm Hg, SD 8 versus −12 mm Hg, SD 12; p = 0.51) from baseline to 3‑h follow-up was similar in the theophylline group and the control group
PMID 34259904 · one of two readings recorded this
early clinical improvement, NIHSS improvement of 4 points or more from baseline to 3 h, proportion of patients
no effect, 1 (8%) versus 2 (18%), p = 1.0, p = 1, n = 24
Not recorded as a finding: nih-stroke-scale node is the total score; this is a dichotomised improvement responder proportion
Clinical improvement at 3‑h follow-up was present in 1 (8%) patient in the theophylline group and 2 patients (18%) in the control group (p = 1.0).
PMID 34259904 · one of two readings recorded this
heart rate change from baseline to 3 h follow-up
increases, p = 0.05
The change in heart rate from baseline to 3‑h follow-up was significantly different (p < 0.05) in the theophylline group (mean increase by 11 beats per minute, SD 26) compared to the control group (mean decrease by 9 beats per minute, SD 14)
PMID 34259904 · one of two readings recorded this
NIHSS score at 24 h
Mean NIHSS score at 24 h (SD) | 7 (6) | 5 (5)
PMID 34259904 · one of two readings recorded this
rCBF at 3 h follow-up
no effect, p = 0.28
rCBF—(SD) | 0.88 (0.23) | 0.78 (0.34) | 0.28a | 0.82 (0.17) | 0.80 (0.21) | 0.66a | 0.99 (0.05) | 0.98 (0.04) | 0.47a
PMID 34259904 · one of two readings recorded this
rCBF at 3 h follow-up
no effect, p = 0.66
rCBF—(SD) | 0.88 (0.23) | 0.78 (0.34) | 0.28a | 0.82 (0.17) | 0.80 (0.21) | 0.66a | 0.99 (0.05) | 0.98 (0.04) | 0.47a
PMID 34259904 · one of two readings recorded this
rCBF at 3 h follow-up
no effect, p = 0.47
rCBF—(SD) | 0.88 (0.23) | 0.78 (0.34) | 0.28a | 0.82 (0.17) | 0.80 (0.21) | 0.66a | 0.99 (0.05) | 0.98 (0.04) | 0.47a
PMID 34259904 · one of two readings recorded this
rCBF at baseline
no effect, p = 0.16
rCBF—(SD) | 0.67 (0.28) | 0.50 (0.13) | 0.16a | 0.70 (0.21) | 0.63 (0.17) | 0.51a | 1.01 (0.07) | 1.02 (0.04) | 0.14a
PMID 34259904 · one of two readings recorded this
rCBF at baseline
no effect, p = 0.51
rCBF—(SD) | 0.67 (0.28) | 0.50 (0.13) | 0.16a | 0.70 (0.21) | 0.63 (0.17) | 0.51a | 1.01 (0.07) | 1.02 (0.04) | 0.14a
PMID 34259904 · one of two readings recorded this
rCBF at baseline
no effect, p = 0.14
rCBF—(SD) | 0.67 (0.28) | 0.50 (0.13) | 0.16a | 0.70 (0.21) | 0.63 (0.17) | 0.51a | 1.01 (0.07) | 1.02 (0.04) | 0.14a
PMID 34259904 · one of two readings recorded this
rCBF change from baseline to 3 h
no effect, p = 0.65
rCBF—(SD) | 0.21 (0.33) | 0.27 (0.36) | 0.65b | 0.11 (0.21) | 0.17 (0.16) | 0.51b | −0.02 (0.05) | −0.04 (0.04) | 0.20b
PMID 34259904 · one of two readings recorded this
rCBF change from baseline to 3 h
no effect, p = 0.51
rCBF—(SD) | 0.21 (0.33) | 0.27 (0.36) | 0.65b | 0.11 (0.21) | 0.17 (0.16) | 0.51b | −0.02 (0.05) | −0.04 (0.04) | 0.20b
PMID 34259904 · one of two readings recorded this
rCBF change from baseline to 3 h
no effect, p = 0.2
rCBF—(SD) | 0.21 (0.33) | 0.27 (0.36) | 0.65b | 0.11 (0.21) | 0.17 (0.16) | 0.51b | −0.02 (0.05) | −0.04 (0.04) | 0.20b
PMID 34259904 · one of two readings recorded this
rCBV at 3 h follow-up
increases, p = 0.01
rCBV—(SD) | 0.97 (0.29) | 0.73 (0.15) | 0.01a | 0.97 (0.23) | 0.93 (0.38) | 0.66a | 1.03 (0.09) | 0.99 (0.07) | 0.34a
PMID 34259904 · one of two readings recorded this
rCBV at 3 h follow-up
no effect, p = 0.66
rCBV—(SD) | 0.97 (0.29) | 0.73 (0.15) | 0.01a | 0.97 (0.23) | 0.93 (0.38) | 0.66a | 1.03 (0.09) | 0.99 (0.07) | 0.34a
PMID 34259904 · one of two readings recorded this
rCBV at 3 h follow-up
no effect, p = 0.34
rCBV—(SD) | 0.97 (0.29) | 0.73 (0.15) | 0.01a | 0.97 (0.23) | 0.93 (0.38) | 0.66a | 1.03 (0.09) | 0.99 (0.07) | 0.34a
PMID 34259904 · one of two readings recorded this
rCBV at baseline
no effect, p = 0.34
rCBV—(SD) | 0.93 (0.27) | 0.86 (0.22) | 0.34a | 1.14 (0.31) | 1.01 (0.31) | 0.28a | 1.06 (0.09) | 1.07 (0.09) | 0.75a
PMID 34259904 · one of two readings recorded this
rCBV at baseline
no effect, p = 0.28
rCBV—(SD) | 0.93 (0.27) | 0.86 (0.22) | 0.34a | 1.14 (0.31) | 1.01 (0.31) | 0.28a | 1.06 (0.09) | 1.07 (0.09) | 0.75a
PMID 34259904 · one of two readings recorded this
rCBV at baseline
no effect, p = 0.75
rCBV—(SD) | 0.93 (0.27) | 0.86 (0.22) | 0.34a | 1.14 (0.31) | 1.01 (0.31) | 0.28a | 1.06 (0.09) | 1.07 (0.09) | 0.75a
PMID 34259904 · one of two readings recorded this
rCBV change from baseline to 3 h
increases, p = 0.04
rCBV—(SD) | 0.05 (0.18) | −0.14 (0.24) | 0.04b | −0.17 (0.25) | −0.08 (0.20) | 0.32b | −0.04 (0.07) | −0.08 (0.07) | 0.18b
PMID 34259904 · one of two readings recorded this
rCBV change from baseline to 3 h
no effect, p = 0.32
rCBV—(SD) | 0.05 (0.18) | −0.14 (0.24) | 0.04b | −0.17 (0.25) | −0.08 (0.20) | 0.32b | −0.04 (0.07) | −0.08 (0.07) | 0.18b
PMID 34259904 · one of two readings recorded this
rCBV change from baseline to 3 h
no effect, p = 0.18
rCBV—(SD) | 0.05 (0.18) | −0.14 (0.24) | 0.04b | −0.17 (0.25) | −0.08 (0.20) | 0.32b | −0.04 (0.07) | −0.08 (0.07) | 0.18b
PMID 34259904 · one of two readings recorded this
recanalization in patients with large vessel occlusion
no effect, p = 0.11
Recanalization was found in 7 of 7 patients with LVO in the theophylline group and in 2 of 4 in the control group (p = 0.11)
PMID 34259904 · one of two readings recorded this
recanalization (TIMI 2-3) at 3 h
Recanalization (TIMI 2–3) at 3 h—no. (%)a | 3 (43) | 3 (75)
PMID 34259904 · one of two readings recorded this
relative cerebral blood volume (rCBV) in the infarct core, change from baseline to 3-h follow-up, perfusion-weighted MRI, theophylline versus placebo as add-on to thrombolysis
mean change 0.05 (SD 0.18) theophylline versus -0.14 (SD 0.24) control
Not recorded as a finding: this platform holds no node for the endpoint
Likewise, there was a statistically significant difference (p < 0.04) regarding the mean rCBV change from baseline to 3‑h follow-up in the theophylline group (mean = 0.05; SD = 0.18) compared to the control group (mean = −0.14; SD = 0.24; Table 2).
PMID 34259904 · one of two readings recorded this
relative cerebral blood volume (rCBV) in the infarct core, perfusion-weighted MRI, change from baseline to 3 h
increases, mean 0.05 (SD 0.18) versus -0.14 (SD 0.24), p < 0.04, n = 24
Not recorded as a finding: no outcome node for MRI perfusion parameters (rCBF, rCBV, rMTT)
Likewise, there was a statistically significant difference (p < 0.04) regarding the mean rCBV change from baseline to 3‑h follow-up in the theophylline group (mean = 0.05; SD = 0.18) compared to the control group (mean = −0.14; SD = 0.24; Table 2).
PMID 34259904 · one of two readings recorded this
rMTT at 3 h follow-up
no effect, p = 0.34
rMTT—(SD), sec | 1.87 (2.17) | 1.18 (2.53) | 0.34a | 2.22 (1.85) | 2.34 (1.95) | 0.88a | 0.34 (0.36) | 0.12 (0.29) | 0.11a
PMID 34259904 · one of two readings recorded this
rMTT at 3 h follow-up
no effect, p = 0.88
rMTT—(SD), sec | 1.87 (2.17) | 1.18 (2.53) | 0.34a | 2.22 (1.85) | 2.34 (1.95) | 0.88a | 0.34 (0.36) | 0.12 (0.29) | 0.11a
PMID 34259904 · one of two readings recorded this
rMTT at 3 h follow-up
no effect, p = 0.11
rMTT—(SD), sec | 1.87 (2.17) | 1.18 (2.53) | 0.34a | 2.22 (1.85) | 2.34 (1.95) | 0.88a | 0.34 (0.36) | 0.12 (0.29) | 0.11a
PMID 34259904 · one of two readings recorded this
rMTT at baseline
no effect, p = 0.21
rMTT—(SD), sec | 4.7 (3.6) | 6.5 (3.8) | 0.21a | 6.02 (3.17) | 5.68 (3.17) | 0.93a | 0.34 (0.64) | 0.35 (0.60) | 0.58a
PMID 34259904 · one of two readings recorded this
rMTT at baseline
no effect, p = 0.93
rMTT—(SD), sec | 4.7 (3.6) | 6.5 (3.8) | 0.21a | 6.02 (3.17) | 5.68 (3.17) | 0.93a | 0.34 (0.64) | 0.35 (0.60) | 0.58a
PMID 34259904 · one of two readings recorded this
rMTT at baseline
no effect, p = 0.58
rMTT—(SD), sec | 4.7 (3.6) | 6.5 (3.8) | 0.21a | 6.02 (3.17) | 5.68 (3.17) | 0.93a | 0.34 (0.64) | 0.35 (0.60) | 0.58a
PMID 34259904 · one of two readings recorded this
rMTT change from baseline to 3 h
no effect, p = 0.17
rMTT—(SD), sec | −2.82 (4.26) | −5.32 (4.43) | 0.17b | −3.80 (4.17) | −3.35 (3.16) | 0.77b | −0.00 (0.64) | −0.22 (0.54) | 0.39b
PMID 34259904 · one of two readings recorded this
rMTT change from baseline to 3 h
no effect, p = 0.77
rMTT—(SD), sec | −2.82 (4.26) | −5.32 (4.43) | 0.17b | −3.80 (4.17) | −3.35 (3.16) | 0.77b | −0.00 (0.64) | −0.22 (0.54) | 0.39b
PMID 34259904 · one of two readings recorded this
rMTT change from baseline to 3 h
no effect, p = 0.39
rMTT—(SD), sec | −2.82 (4.26) | −5.32 (4.43) | 0.17b | −3.80 (4.17) | −3.35 (3.16) | 0.77b | −0.00 (0.64) | −0.22 (0.54) | 0.39b
PMID 34259904 · one of two readings recorded this
systolic blood pressure change from baseline to 3 h follow-up
no effect, p = 0.62
The change in systolic blood pressure (−12 mm Hg, SD 14 versus −8 mm Hg, SD 25; p = 0.62) and the diastolic blood pressure (−9 mm Hg, SD 8 versus −12 mm Hg, SD 12; p = 0.51) from baseline to 3‑h follow-up was similar in the theophylline group and the control group
PMID 34259904 · one of two readings recorded this
volume of final FLAIR lesion at 24 h
Mean volume of final FLAIR lesion at 24 h—ml (SD) | 24.8 (24.8) | 14.7 (14.9)
PMID 34259904 · one of two readings recorded this
adverse events reported
no effect
Similarly, there were no reported adverse events
PMID 34894449 · one of two readings recorded this
Global Rating of Smell Change, patient-reported, proportion of responders (slightly, somewhat or much better)
unclear, difference 3.3%, 95% CI -35.6% to 42.3%, n = 22
Not recorded as a finding: cgi-improvement-score node is the clinician's CGI-I rating; this is a patient-reported transitional item formatted on the CGI-Change scale and analysed as a responder proportion; no node for the responder proportion
For the primary outcome measure, slightly more patients in the theophylline group (33%, 4/12) reported improved smell compared to the placebo group (30%, 3/10) (difference 3.3%, 95% CI −35.6% to 42.3%).
PMID 34894449 · one of two readings recorded this